WO2008109506A8 - Nucleic acid compounds for inhibiting jun gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting jun gene expression and uses thereof Download PDF

Info

Publication number
WO2008109506A8
WO2008109506A8 PCT/US2008/055627 US2008055627W WO2008109506A8 WO 2008109506 A8 WO2008109506 A8 WO 2008109506A8 US 2008055627 W US2008055627 W US 2008055627W WO 2008109506 A8 WO2008109506 A8 WO 2008109506A8
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
jun
gene expression
jun gene
acid compounds
Prior art date
Application number
PCT/US2008/055627
Other languages
French (fr)
Other versions
WO2008109506B1 (en
WO2008109506A1 (en
WO2008109506A9 (en
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc, Steven C Quay, James Mcswiggen, Narendra K Vaish, Mohammad Ahmadian filed Critical Mdrna Inc
Publication of WO2008109506A1 publication Critical patent/WO2008109506A1/en
Publication of WO2008109506B1 publication Critical patent/WO2008109506B1/en
Publication of WO2008109506A9 publication Critical patent/WO2008109506A9/en
Publication of WO2008109506A8 publication Critical patent/WO2008109506A8/en
Priority to US12/552,082 priority Critical patent/US20100105134A1/en
Priority to US13/327,545 priority patent/US20130011922A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing JUN gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a JUN mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a JUN gene in a cell or in a subject to treat a JUN-related disease.
PCT/US2008/055627 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting jun gene expression and uses thereof WO2008109506A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/552,082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13/327,545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93494007P 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007P 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US1516607P 2007-12-19 2007-12-19
US61/015,166 2007-12-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055697 Continuation-In-Part WO2008109547A2 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting tymp gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055572 Continuation-In-Part WO2008106664A2 (en) 2007-03-01 2008-02-29 Human behavioral modeling and simulation framework
AU2009212920A Division AU2009212920A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US12/552,082 Continuation-In-Part US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (4)

Publication Number Publication Date
WO2008109506A1 WO2008109506A1 (en) 2008-09-12
WO2008109506B1 WO2008109506B1 (en) 2008-12-18
WO2008109506A9 WO2008109506A9 (en) 2009-02-19
WO2008109506A8 true WO2008109506A8 (en) 2009-07-16

Family

ID=39620195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055627 WO2008109506A1 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting jun gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109506A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876637B2 (en) 2006-10-18 2016-03-02 マリーナ バイオテック,インコーポレイテッド Nicked or gapped nucleic acid molecules and their use
GB0720976D0 (en) * 2007-10-26 2007-12-05 Medical Res Council Treatment of inflammatory disease
AU2013216852A1 (en) * 2012-02-08 2014-08-21 Isis Pharmaceuticals, Inc. Methods and compositions for modulating Factor VII expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
EP1592791A2 (en) * 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
EP1605978B1 (en) * 2003-03-07 2010-09-01 Alnylam Pharmaceuticals Inc. Therapeutic compositions
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
US8329888B2 (en) * 2006-03-23 2012-12-11 Santaris Pharma A/S Small internally segmented interfering RNA
JP5876637B2 (en) * 2006-10-18 2016-03-02 マリーナ バイオテック,インコーポレイテッド Nicked or gapped nucleic acid molecules and their use

Also Published As

Publication number Publication date
WO2008109506B1 (en) 2008-12-18
WO2008109506A1 (en) 2008-09-12
WO2008109506A9 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2008109465A3 (en) Nucleic acid compounds for inhibiting fgfr gene expression and uses thereof
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2008109352A3 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2008109350A3 (en) Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
WO2008109372A3 (en) Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109366A3 (en) Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
WO2008109506A8 (en) Nucleic acid compounds for inhibiting jun gene expression and uses thereof
WO2008109443A3 (en) Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2008109546A3 (en) Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
WO2008109558A3 (en) Nucleic acid compounds for inhibiting tlr gene expression and uses thereof
WO2008109495A3 (en) Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
WO2008109487A3 (en) Nucleic acid compounds for inhibiting mme gene expression and uses thereof
WO2008109493A3 (en) Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
WO2008109364A3 (en) Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
WO2008109368A3 (en) Nucleic acid compounds for inhibiting vegfr gene expression and uses thereof
WO2008109370A3 (en) Nucleic acid compounds for inhibiting srd5a1 gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731224

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731224

Country of ref document: EP

Kind code of ref document: A1